Table 3. Frequencies of Short-term Inflammation Control and Durable Disease Control in paediatric uveitis patients treated with mycophenolate mofetil monotherapy, according to previous immunomodulatory therapy received.
| Previous IMTs | Durable Disease Control (n/N (%))a | Short-term Inflammation Control (n/N (%))b | Sum of two groups (n/N (%)) |
|---|---|---|---|
| None | 1/4 (25.0%) | 2/4 (50.0%) | 3/4 (75.0%) |
| Methotrexate | 24/48 (50.0%) | 11/48 (22.9%) | 35/48 (72.9%) |
| Cyclosporine | 1/4 (25.0%) | 1/4 (25.0%) | 2/4 (50.0%) |
| Adalimumab | 1/2 (50.0%) | 0/2 (0.0%) | 1/2 (50.0%) |
| Infliximab | 0/2 (0.0%) | 1/2 (50.0%) | 1/2 (50.0%) |
| Etanercept | 0/1 (0.0%) | 0/1 (0.0%) | 0/1 (0.0%) |
Abbreviation: IMT, immunomodulatory therapy.
a
Defined as patients whose uveitis remained quiescent for at least 2 years on MMF monotherapy with no more than 2 flare-ups successfully treated with either an increase of the MMF dosage or a short duration (<1 month) of corticosteroids.
b
Defined as patients whose uveitis remained quiescent for less than 2 years with no more than 1 flare-up successfully treated with either an increase of the MMF dosage or a short duration (<1 month) of corticosteroids, or those who initially achieved inflammation control but had to discontinue MMF because of significant adverse effects.
n/N, no. of patients who met the criteria/no. of patients who earlier had been on IMT.